The role of glucagon-like peptide(GLP-1)receptor agonists in the treatment of type 2 diabetes mellitus has been widely recognized. In order to improve their efficacy and safety, a number of molecularly modified agents have emerged in recent years, hoping to achieve better results through the mechanism complementation between several gastrointestinal hormones. As a novel GLP-1/gastric inhibitory peptide(GIP)dual receptor agonist, Tirzepatide has been proved by many studies to be able to control blood glucose, reduce body weight, and has potential application value in the treatment of chronic neurodegenerative diseases and non-alcoholic steatohepatitis. Its efficacy and safety are superior to GLP-1 receptor agonists, and it has broad application prospects.